@[email protected]M to [email protected] • 3 years agoCRISPR-Cas9 gene editing successful for a patient with Sickle Cell Disease and another patient with transfusion dependent β-Thalassemia - More than a year later, both patients had clinically improvedwww.nejm.orgexternal-linkmessage-square0fedilinkarrow-up10arrow-down10
arrow-up10arrow-down1external-linkCRISPR-Cas9 gene editing successful for a patient with Sickle Cell Disease and another patient with transfusion dependent β-Thalassemia - More than a year later, both patients had clinically improvedwww.nejm.org@[email protected]M to [email protected] • 3 years agomessage-square0fedilink